CHEST Issues OSA Guidance for Pregnancy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CHEST Issues OSA Guidance for Pregnancy

Guideline recommends screening, diagnosis, positive airway pressure therapy, and postpartum reassessment while highlighting the very low certainty of available evidence.

  • By

  • Kathryn Wighton

  • August 11, 2026

  • 4 min

Share

Objective:

To provide clinical practice guidelines on the management of obstructive sleep apnea (OSA) during pregnancy.

Approach:
  • Systematic Review: The CHEST panel conducted a systematic review addressing nine population, intervention, comparator, and outcome questions using the Grading of Recommendations, Assessment, Development, and Evaluations framework.
Key Findings:
  • OSA has been associated with hypertensive disorders of pregnancy, gestational diabetes, severe cardiovascular morbidity, intensive care unit admission, preterm birth, adverse fetal growth, neonatal ICU admission, and congenital anomalies.
Interpretation:

The guidance emphasizes the necessity for further research due to low evidence levels regarding screening and treatment of OSA in pregnancy, as highlighted by lead guideline author Carolyn M. D'Ambrosio, MD.

Limitations:
  • Most recommendations are based on low-certainty evidence.
  • Limited availability of pregnancy-specific screening tools and treatment data.
Conclusion:

Future research is necessary to address knowledge gaps in OSA management during pregnancy.

Sources:

Original Source(s)

CHEST Issues OSA Guidance for Pregnancy

  • by Kathryn Wighton

  • August 11, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.